Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
A Study to Assess the Reversal of the Anticoagulant Effects of JNJ-70033093 by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

(rFVIIa) in healthy participants as measured by changes from baseline of the coagulation testing parameters (activated partial thromboplastin time [aPTT] and thrombin generation assay [TGA]).

  • 0 views
  • 05 Jun, 2021
  • 1 location
The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots

), factor VIIIc, activated partial thromboplastin time (aPTT) and activated partial thromboplastin time plus activated protein C (aPTT + APC). Both groups will undergo a GYN exam with screening

d-dimer
thrombosis
thrombin
copper
protein c
  • 131 views
  • 07 Nov, 2020
  • 1 location
Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis

A randomized cohort study applied to patients with mechanical heart valve prosthesis who will be delivered by caesarean section at or after 28 weeks of gestation . Using a table of random numbers, participants will be divided into 2 equal groups. Group A (57 patients) in which warfarin will be …

  • 0 views
  • 29 Apr, 2021
  • 1 location
Heparin Anticoagulation in Septic Shock

This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.

heparin
systolic blood pressure
arterial ph
renal injury
vasopressin
  • 121 views
  • 04 Feb, 2021
  • 50 locations
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

evaluate the safety and tolerability of BIVV001 treatment. To assess the PK of BIVV001 based on the one stage activated partial thromboplastin time (aPTT) and two-stage chromogenic FVIII activity

  • 0 views
  • 03 May, 2021
  • 4 locations
A Phase 3 Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein Efanesoctocog Alfa (BIVV001) in Patients With Severe Hemophilia A

the 1-stage activated partial thromboplastin time (aPTT) and 2-stage chromogenic FVIII activity assays

treatment regimen
severe haemophilia a
coagulant
von willebrand factor
von willebrand's disease
  • 13 views
  • 27 Feb, 2021
  • 3 locations
Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism

> Patients (n=60) with acute intermediary-high risk PE will be randomized 1:1 to UFH (bolus 80 international units per kilo (IU/kg)) followed by 18 IU/kg/hour until activated partial thromboplastin time

heparin
alteplase
clot
angiography
acute pulmonary embolism
  • 1 views
  • 06 May, 2021
  • 1 location
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

This is a pre-surgical study involving subjects with local advanced bladder cancer, who are candidates for neoadjuvant therapy. It is a single-arm phase II portion.

measurable disease
bladder tumor
gemcitabine
carcinoma
radical cystectomy
  • 0 views
  • 25 Jun, 2021
  • 1 location
Investigation of Systemic and Regional Haemostasis During Liver Transplantation by Comparing ClotPro and TEG

The purpose of the research is to compare the global and the portal haemostasis during liver transplantation by functional investigations using TEG and ClotPro tests. The study aims at revealing important coagulation-associated links affecting the outcome of the liver transplant surgery.

  • 0 views
  • 24 Jan, 2021
  • 1 location
Extracorporeal Life Support and Modification of Hemostasis

To evaluate change in coagulation tests during a 48-h period after initiation VV-ECMO and VA-ECMO. (ECMO= Extra Corporeal Membrane Oxygenator) Assessment of bleeding during Veno-Venous Extracoporeal Membrane Oxygenator (VV-ECMO) and Veno-Arterial Extracoporeal Membrane Oxygenator (VA-ECMO).

fibrinogen
aptt
haemostasis
tissue plasminogen activator
  • 0 views
  • 12 Jun, 2021
  • 4 locations